Transthyretin Cardiac Amyloidosis: Diagnosis, Imaging, and the Therapeutic Frontier
Transthyretin cardiac amyloidosis (ATTR-CM) has moved from autopsy curiosity to a mainstream differential in heart failure with preserved ejection fraction.
Population estimates suggest that a meaningful minority of older adults hospitalized for heart failure with preserved ejection fraction harbor unrecognized wild-type disease.
The shift from a uniformly fatal diagnosis to one with three approved disease-modifying drugs has happened almost entirely within the last seven years.
This review summarizes the clinical clues, the current imaging hierarchy including emerging PET tracers, the approved treatment landscape, and the antibody- and gene-editing-based therapies now advancing through phase 3 trials.
Clinical Tell-Tale Features
The single most useful diagnostic habit in ATTR-CM is pattern recognition across organ systems rather than reliance on any one cardiac finding.
A history of bilateral carpal tunnel syndrome frequently precedes overt cardiac disease by roughly a decade and should prompt a deliberate look-back in any patient with unexplained left ventricular hypertrophy.
Lumbar spinal stenosis, atraumatic biceps tendon rupture, and disproportionate need for hip or knee arthroplasty round out the classic orthopedic triad described in the ACC expert consensus pathway on cardiac amyloidosis.
A so-called "natural cure" of hypertension, in which a previously well-controlled patient needs progressive antihypertensive de-escalation, is a clinical clue that deserves more attention than it typically receives.
Intolerance to standard heart-failure pharmacotherapy, particularly beta-blockade, reflects the fixed, preload-dependent stroke volume of the infiltrated ventricle rather than true rate-related decompensation.
Low QRS voltage relative to left ventricular wall thickness is a classic but insensitive sign, present in well under half of confirmed cases.
Paradoxical low-flow, low-gradient aortic stenosis in an older patient is now a recognized indication for opportunistic amyloid screening, since the two diseases coexist far more often than chance would predict.
Diagnostic Workup: From Suspicion to Confirmation
Every workup begins with excluding a monoclonal protein, since light-chain disease is a hematologic emergency that scintigraphy alone cannot rule out.
The screening triad is serum free light chains, serum immunofixation electrophoresis, and urine immunofixation electrophoresis.
If all three are negative, bone-avid radionuclide scintigraphy can establish a non-invasive ATTR-CM diagnosis without biopsy.
Grade 2 or grade 3 myocardial uptake on single-photon emission CT, obtained two to three hours after injection, is considered diagnostic per the ACC consensus pathway.
If the monoclonal screen is positive, or if scintigraphy shows only grade 0–1 uptake despite strong clinical suspicion, tissue biopsy with mass spectrometry typing becomes mandatory.
Genetic sequencing of the TTR gene is recommended in every confirmed case to distinguish hereditary (ATTRv) from wild-type (ATTRwt) disease and to trigger cascade testing of first-degree relatives.
Two ATTR genotypes, p.Phe84Leu and p.Val50Met, are recognized causes of false-negative scintigraphy and should prompt biopsy when suspicion remains high despite a negative scan.
Imaging: Available and Emerging Tracers
Echocardiography remains the first imaging test obtained for nearly every patient and typically shows concentric left ventricular hypertrophy with biatrial enlargement and a restrictive filling pattern.
The relative apical sparing strain pattern on speckle-tracking echocardiography is sensitive and visually distinctive, though it performs better as a qualitative gestalt than as a rigid quantitative cutoff.
Cardiac MRI adds diffuse, often subendocardial-to-transmural late gadolinium enhancement plus elevated native T1 and extracellular volume, and a published comparison found native T1 and ECV measurements outperformed strain-based apical sparing for separating amyloidosis from hypertrophic cardiomyopathy.
Bone-avid scintigraphy using 99mTc-pyrophosphate, DPD, or HMDP remains the diagnostic workhorse precisely because it can establish the diagnosis without biopsy when the monoclonal screen is negative.
A 2025 multisociety update emphasized that three-hour SPECT/CT imaging, rather than one-hour planar-only acquisition, gives the most balanced sensitivity and specificity for grading uptake.
Beyond bone tracers, a family of amyloid-binding PET agents first developed for cerebral amyloid imaging is now being repurposed for the heart, including florbetapir, flutemetamol, and Pittsburgh compound B.
[18F]Florbetaben received FDA Fast Track designation specifically for cardiac amyloidosis diagnosis, with an ongoing phase 3 validation trial comparing its diagnostic accuracy against standard-of-care confirmation.
An investigational pan-amyloid tracer, 124I-evuzamitide, is notable because it binds amyloid fibrils irrespective of the precursor protein, raising the possibility of a single whole-body scan that detects AL and ATTR disease alike.
Early antibody-depletion trials have used serial PYP scintigraphy and CMR-derived extracellular volume as surrogate markers of falling cardiac amyloid burden, although one case report found imaging improvement without matching hemodynamic benefit, underscoring that imaging response and clinical response are not yet interchangeable endpoints.
| Modality | Primary Signal | Strength | Limitation |
|---|---|---|---|
| Echocardiography | Concentric LVH, apical-sparing strain | First-line, ubiquitous, no contrast | Lower specificity in isolation; subtle in early disease |
| Cardiac MRI | Elevated native T1/ECV, diffuse LGE | Best at excluding HCM and other infiltrative disease | Gadolinium limits in renal impairment; cost |
| 99mTc-PYP / DPD / HMDP scintigraphy | Perugini grade 2–3 uptake ≥ rib | Diagnostic without biopsy when monoclonal screen negative | False positives (prior MI, hydroxychloroquine); false negatives in select variants and early disease |
| Amyloid PET (florbetapir, florbetaben, flutemetamol) | Quantitative SUV / myocardial retention | Whole-body assessment; potential treatment-response biomarker | Mostly investigational for cardiac indication; limited site availability |
| 124I-evuzamitide PET | Pan-amyloid fibril binding | Subtype-agnostic; single scan for AL and ATTR | Investigational; isotope logistics restrict availability |
Current Treatment: Stabilizers and Silencers
Three drugs now carry FDA approval specifically for ATTR-CM, and all three act upstream of fibril deposition rather than reversing existing amyloid.
Tafamidis was the first approved agent and works as a TTR tetramer stabilizer, binding the thyroxine pocket to prevent the dissociation step that precedes misfolding.
Acoramidis is a newer stabilizer designed for near-complete tetramer occupancy, and preclinical work cited in a recent review found it stabilized roughly 98% of wild-type TTR tetramers in serum compared with about 49% for tafamidis, though the clinical significance of that biochemical gap remains uncertain.
Vutrisiran works by an entirely different mechanism, an RNA-interference therapy that silences hepatic TTR messenger RNA and lowers production of both wild-type and variant protein at the source.
Vutrisiran's ATTR-CM approval made it the first agent cleared by the FDA for both polyneuropathy and cardiomyopathy phenotypes of ATTR amyloidosis, based on a roughly 28% reduction in a composite of all-cause mortality and recurrent cardiovascular events.
A frequently overlooked point is that the three pivotal trials enrolled meaningfully different populations, with the tafamidis trial skewed toward more severe heart failure, which makes naive cross-trial efficacy comparisons statistically unsound.
An older, far less expensive stabilizer, diflunisal, remains an off-label option in resource-limited settings but carries renal and gastrointestinal risk that limits its use in this older, comorbid population.
General heart-failure pharmacology requires adaptation in ATTR-CM, since beta-blockers are frequently poorly tolerated and mineralocorticoid antagonism has more retrospective support than ACE inhibition or ARNI therapy in this specific phenotype.
| Drug | Mechanism | Pivotal Trial | Administration | Approval Landmark |
|---|---|---|---|---|
| Tafamidis | TTR tetramer stabilizer | ATTR-ACT | Oral, once daily | First ATTR-CM approval, 2019 |
| Acoramidis | Near-complete TTR stabilizer | ATTRibute-CM | Oral, twice daily | Approved Nov 2024 |
| Vutrisiran | Hepatic TTR-silencing siRNA | HELIOS-B | Subcutaneous, every 3 months | ATTR-CM indication added Mar 2025; first agent spanning ATTR-PN and ATTR-CM |
A 74-year-old man presents with progressive dyspnea and is found to have HFpEF with an echocardiogram showing 15 mm septal thickness and reduced longitudinal strain with apical sparing.
His surgical history includes bilateral carpal tunnel release eight years earlier and a lumbar laminectomy, and he has needed his antihypertensives steadily reduced over the past two years.
Serum free light chains and immunofixation studies are unremarkable, prompting bone scintigraphy that shows grade 3 myocardial uptake on SPECT/CT.
Genetic testing confirms wild-type disease, and he is started on a TTR-stabilizing or silencing agent while his family is counseled that cascade screening is unnecessary given the wild-type result.
Future Directions: Depleters and Gene Editing
Stabilizers and silencers slow disease progression, but neither removes amyloid already deposited in the myocardium, which has motivated a parallel push toward fibril-clearing antibodies.
NI006 (also designated ALXN-2220) is a recombinant anti-ATTR antibody that selectively binds misfolded, amyloid-conformation TTR and triggers antibody-mediated phagocytic clearance while sparing native tetramers.
Its phase 1 trial reported no drug-related serious adverse events and showed reductions in cardiac tracer uptake and extracellular volume over twelve months, alongside falling NT-proBNP and troponin levels.
Coramitug is a second amyloid-depleting antibody targeting a distinct TTR epitope, and its phase 2 trial in 105 patients with ATTR-CM met its NT-proBNP endpoint at 52 weeks while missing the co-primary six-minute walk distance endpoint, leading to an FDA Fast Track designation and a phase 3 program now enrolling roughly 1,280 patients.
On the gene-editing side, nexiguran ziclumeran (nex-z, formerly NTLA-2001) uses in vivo CRISPR-Cas9 to permanently inactivate the hepatic TTR gene after a single intravenous infusion.
Longer-term phase 1 follow-up reported in an Intellia Therapeutics update showed mean serum TTR reductions of roughly 90% sustained out to three years after a single dose.
The phase 3 cardiomyopathy program was placed on clinical hold in late October 2025 after a patient developed grade 4 liver transaminase elevation, and the related polyneuropathy trial's hold was subsequently lifted by the FDA in January 2026 with enhanced liver-monitoring safeguards, while the cardiomyopathy trial hold remained under active discussion at that time.
This episode is a useful reminder that durable, one-time gene-editing approaches carry a different risk calculus than reversible oral or injectable therapies, particularly in a population that is elderly and frequently has competing comorbidity.
Looking further out, combination strategies that pair a stabilizer or silencer to halt new fibril formation with an antibody depleter to clear existing deposits represent the most plausible path toward true disease regression rather than mere stabilization.
ATTR-CM should be on the differential for any older patient with HFpEF, especially when carpal tunnel syndrome, spinal stenosis, biceps rupture, or low-flow low-gradient aortic stenosis appear alongside cardiac findings.
A negative monoclonal protein screen plus grade 2–3 bone scintigraphy uptake confirms the diagnosis without biopsy in most cases, and genetic testing should follow in every confirmed patient.
Three disease-modifying drugs are now approved, working through tetramer stabilization or hepatic TTR silencing, while amyloid-depleting antibodies and one-time CRISPR-based gene editing are advancing through later-phase trials with a safety profile that still warrants close monitoring.
References
- American College of Cardiology – 2023 Expert Consensus Decision Pathway on Cardiac Amyloidosis: Key Points
- Journal of the American College of Cardiology – Transthyretin Amyloid Cardiomyopathy: State-of-the-Art Review (PMC)
- Taiwan Society of Cardiology / Society of Nuclear Medicine – 2025 Consensus on 99mTc-Pyrophosphate Scintigraphy (PMC)
- Transthyretin Amyloid Cardiomyopathy – 2025 Update on Diagnosis and Emerging Therapies (PMC)
- ClinicalTrials.gov – Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac Amyloidosis (NCT05184088)
- Pharmacy Times – FDA Fast Track Designation for [18F]Florbetaben
- TCTMD – Vutrisiran FDA Approval Coverage for ATTR-CM
- Disease-Modifying Therapies for ATTR-CM: Current and Emerging Medications (PMC)
- Coramitug Phase 2 Randomized Trial in ATTR-CM (PMC)
- Intellia Therapeutics – Longer-Term Phase 1 Data for Nexiguran Ziclumeran
- Intellia Therapeutics – FDA Lift of Clinical Hold on MAGNITUDE-2
- Apical Sparing in Routine Echocardiography: Occurrence and Clinical Significance (PMC)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.